Why is UroGen Pharma stock sliding today?

Shares of UroGen Pharma fell 16.5% in afternoon trading after the bladder-cancer specialist reported third-quarter 2026 results before the open that disappointed investors on both the top line and the forward outlook for its legacy product. While the company posted a narrower-than-expected net loss of $0.03 per share — beating the consensus estimate of -$0.05 — total revenue of $89 million came in just below the $90.58 million Wall Street had forecast. The more jarring blow was management’s decision to trim full-year 2026 JELMYTO revenue guidance to approximately $90 million, down from a prior range of $97 million to $101 million, citing a one-time unfavorable CMS gross-to-net adjustment and growing competitive pressure from clinical trial enrollment in the low-grade upper tract urothelial cancer space.

The selloff was compounded by a sharp jump in research and development expenses to $26 million for the quarter, up 86% year-over-year, which raised questions about the pace of cash consumption even as the company expressed confidence in reaching profitability by year-end. On a more constructive note, H.C. Wainwright reiterated its Buy rating and $75 price target on the stock following the initiation of a Phase 1 trial for UGN-501, a next-generation oncolytic virus candidate for non-muscle invasive bladder cancer, though that endorsement was insufficient to offset the negative reaction to the guidance cut. Insider selling activity over the prior 90 days — totaling roughly 65,000 shares — also added a modest headwind to sentiment.

The decline stands in stark contrast to a broadly positive session for U.S. equities, with the S&P 500, Dow Jones, and NASDAQ all posting solid gains, meaning the pressure on URGN is entirely driven by company-specific factors rather than any macro or sector-wide weakness. The stock’s intraday range of $27.55 to $34.17 reflects the sharp repricing that began in pre-market trading and extended through the regular session.

Taken together, a slight revenue miss, a meaningful downward revision to JELMYTO’s annual outlook, and surging operating expenses created a combination that outweighed the positives — including ZUSDURI’s strong 35% sequential revenue growth and a dramatically narrowed net loss — pushing shares to their lowest levels in several weeks and erasing a significant portion of the stock’s year-to-date gains.